Pembrolizumab Beneficial for High-Risk Stage II Melanoma

Pembrolizumab Beneficial for High-Risk Stage II Melanoma

Adjuvant immunotherapy with PD-1 inhibitors (nivolumab or pembrolizumab) in resected stage III/IV melanoma reduces the risk of recurrence by approximately 40% and...

FDA Cancer Treatment Approvals in September 2021

FDA Cancer Treatment Approvals in September 2021

In September, the United States Food and Drug Administration (FDA) granted six new and extended indications for the treatment of patients with...

Pembrolizumab Combo Practice-Changing in Advanced Cervical Cancer

Pembrolizumab Combo Practice-Changing in Advanced Cervical Cancer

The standard of care first-line therapy for persistent, recurrent, or metastatic cervical cancer is platinum-based chemotherapy ± bevacizumab. Although the addition of...

Trastuzumab Deruxtecan New Second-Line Option for HER2+ Metastatic Breast Cancer

Trastuzumab Deruxtecan New Second-Line Option for HER2+ Metastatic Breast Cancer

Every year, the European Society for Medical Oncology (ESMO) Congress is an opportunity for ‘’connecting and engaging those who care about cancer’’....

Genomic Heterogeneity in ctDNA During Therapy Affects Prognosis of mCRC

Genomic Heterogeneity in ctDNA During Therapy Affects Prognosis of mCRC

Molecular screening for actionable alterations, such as RAS, BRAFV600E, and MMR/MSI in metastatic colorectal cancer (mCRC), is key for personalized treatment selection...

Antibiotics Do Not Impact Chemo-Immunotherapy Outcomes in NSCLC

Antibiotics Do Not Impact Chemo-Immunotherapy Outcomes in NSCLC

Immunotherapy with immune checkpoint inhibitors (ICIs), either alone or in combination with chemotherapy, is now the established standard of care in the...